Skip to main content
SpringerLink
Log in

Tumors of the Central Nervous System

  • Protocol
  • First Online:
Clinical Trials in Neurology

Part of the book series: Neuromethods ((NM,volume 138))

  • 586 Accesses

Abstract

Tumors of the central nervous system have a significant impact on the daily living of affected individuals and research studies on this field are essential for understanding their diagnostic techniques and therapeutic effects. This book chapter discusses the findings of a review of the literature conducted in 2015 by using the database engine “Web of Science,” which searched for clinical trials in brain tumors published between 2010 and 2015. The 90 most cited articles in this field were included in the review. Important methodological aspects of these trials are deeply explored in this chapter with the goal of improving the conduction of future research studies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y et al (2013) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006–2010. Neuro Oncol 15(suppl 2):ii1–ii56. https://academic.oup.com/neuro-oncology/article-lookup/doi/10.1093/neuonc/not151

    Article  PubMed  PubMed Central  Google Scholar 

  2. Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J et al (2014) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol 16:iv1–iv63

    Article  PubMed  PubMed Central  Google Scholar 

  3. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820

    Article  PubMed  Google Scholar 

  4. Rogers L, Barani I, Chamberlain M, Kaley TJ, McDermott M, Raizer J et al (2015) Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg 122(1):4–23. http://thejns.org/doi/10.3171/2014.7.JNS131644

    Article  PubMed  PubMed Central  Google Scholar 

  5. McNeill KA (2016) Epidemiology of brain tumors. Neurol Clin 34(4):981–998. https://doi.org/10.1016/j.ncl.2016.06.014

    Article  PubMed  Google Scholar 

  6. Blitshteyn S, Crook JE, Jaeckle KA (2008) Is there an association between meningioma and hormone replacement therapy? J Clin Oncol 26(2):279–282

    Article  CAS  PubMed  Google Scholar 

  7. Walcott BP, Nahed BV, Brastianos PK, Loeffler JS (2013) Radiation treatment for WHO grade II and III meningiomas. Front Oncol 3. http://journal.frontiersin.org/article/10.3389/fonc.2013.00227/abstract

  8. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114(2):97–109. http://link.springer.com/10.1007/s00401-007-0243-4

    Article  PubMed  PubMed Central  Google Scholar 

  9. Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE et al (2014) The epidemiology of glioma in adults: a state of the science review. Neuro Oncol 16(7):896–913

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Tsien C, Moughan J, Michalski JM, Gilbert MR, Purdy J, Simpson J et al (2009) Phase I three-dimensional conformal radiation dose escalation study in newly diagnosed glioblastoma: radiation therapy oncology group trial 98–03. Int J Radiat Oncol Biol Phys 73(3):699–708

    Article  PubMed  Google Scholar 

  11. Lee IH, Piert M, Gomez-Hassan D, Junck L, Rogers L, Hayman J et al (2009) Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys 73(2):479–485

    Article  CAS  PubMed  Google Scholar 

  12. Reardon DA, Norden AD, Desjardins A, Vredenburgh JJ, Herndon JE II, Coan A et al (2012) Phase II study of Gleevec(R) plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. J Neurooncol 106(2):409–415

    Article  CAS  PubMed  Google Scholar 

  13. Terret C, Albrand G, Moncenix G, Droz JP (2011) Karnofsky Performance Scale (KPS) or Physical Performance Test (PPT)? That is the question. Crit Rev Oncol Hematol 77(2):142–147. http://linkinghub.elsevier.com/retrieve/pii/S1040842810000302

    Article  PubMed  Google Scholar 

  14. Wick W, Puduvalli VK, Chamberlain MC, Van Den Bent MJ, Carpentier AF, Cher LM et al (2010) Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 28(7):1168–1174

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Brandes AA, Tosoni A, Franceschi E, Blatt V, Santoro A, Faedi M et al (2009) Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemother Pharmacol 64(4):769–775

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Saraf S, McCarthy BJ, Villano JL (2011) Update on meningiomas. Oncologist 16(11):1604–1613. http://www.ncbi.nlm.nih.gov/pubmed/22028341%5Cnhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC3233296

    Article  PubMed  PubMed Central  Google Scholar 

  17. Combs SE, Hartmann C, Nikoghosyan A, Jäkel O, Karger CP, Haberer T et al (2010) Carbon ion radiation therapy for high-risk meningiomas. Radiother Oncol 95(1):54–59

    Article  CAS  PubMed  Google Scholar 

  18. Hottinger AF, Stupp R, Homicsko K (2014) Standards of care and novel approaches in the management of glioblastoma multiforme. Chin J Cancer 33(1):32–39. http://www.cjcsysu.cn/abstract.asp?fr=doi&idno=20706

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466

    Article  CAS  PubMed  Google Scholar 

  20. Malmström A, Grønberg BH, Marosi C, Stupp R, Frappaz D, Schultz H et al (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13(9):916–926

    Article  CAS  PubMed  Google Scholar 

  21. Minniti G, Clarke E, Cavallo L, Osti M, Esposito V, Cantore G et al (2011) Fractionated stereotactic conformal radiotherapy for large benign skull base meningiomas. Radiat Oncol 6(1):36. http://ro-journal.biomedcentral.com/articles/10.1186/1748-717X-6-36

    Article  PubMed  PubMed Central  Google Scholar 

  22. Stummer W, Reulen HJ, Meinel T, Pichlmeier U, Schumacher W, Tonn JC et al (2008) Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 62(3):564–574

    Article  PubMed  Google Scholar 

  23. Venook AP, Tabernero J (2015) Progression-free survival: helpful biomarker or clinically meaningless end point? J Clin Oncol 33(1):4–6. http://ascopubs.org/doi/10.1200/JCO.2014.57.9557

    Article  PubMed  Google Scholar 

  24. Sluzewski M, Van Rooij WJ, Lohle PN, Beute GN, Peluso JP (2013) Embolization of meningiomas: comparison of safety between calibrated microspheres and polyvinyl-alcohol particles as embolic agents. Am J Neuroradiol 34(4):727–729

    Article  CAS  PubMed  Google Scholar 

  25. Laprie A, Catalaa I, Cassol E, McKnight TR, Berchery D, Marre D et al (2008) Proton magnetic resonance spectroscopic imaging in newly diagnosed glioblastoma: predictive value for the site of postradiotherapy relapse in a prospective longitudinal study. Int J Radiat Oncol Biol Phys 70(3):773–781

    Article  PubMed  Google Scholar 

  26. Johnson DR, Kimmel DW, Burch PA, Cascino TL, Giannini C, Wu W et al (2011) Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma. Neuro Oncol. 13(5):530–535

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Izumoto S, Tsuboi A, Oka Y, Suzuki T, Hashiba T, Kagawa N et al (2008) Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg 108(5):963–971. http://thejns.org/doi/10.3171/JNS/2008/108/5/0963

    Article  CAS  PubMed  Google Scholar 

  28. Hasselbalch B, Lassen U, Hansen S, Holmberg M, Soørensen M, Kosteljanetz M et al (2010) Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro Oncol 12(5):508–516

    PubMed  PubMed Central  CAS  Google Scholar 

  29. Kreissl MC, Hänscheid H, Löhr M, Verburg FA, Schiller M, Lassmann M et al (2012) Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma. Radiat Oncol 7:99. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3439242&tool=pmcentrez&rendertype=abstract

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Trippa F, Maranzano E, Costantini S, Giorni C (2009) Hypofractionated stereotactic radiotherapy for intracranial meningiomas: preliminary results of a feasible trial. J Neurosurg Sci 53(1):7–11

    PubMed  CAS  Google Scholar 

  31. Taal W, Oosterkamp HM, Walenkamp AME, Dubbink HJ, Beerepoot LV, Hanse MCJ et al (2014) Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 15(9):943–953

    Article  CAS  PubMed  Google Scholar 

  32. Carpentier A, Metellus P, Ursu R, Zohar S, Lafitte F, Barrié M et al (2010) Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study. Neuro Oncol 12(4):401–408

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Butowski N, Chang SM, Junck L, DeAngelis LM, Abrey L, Fink K et al (2009) A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). J Neurooncol 91(2):175–182

    Article  CAS  PubMed  Google Scholar 

  34. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R et al (2014) Bevacizumab plus radiotherapy–temozolomide for newly diagnosed glioblastoma. N Engl J Med 370(8):709–722. http://www.nejm.org/doi/10.1056/NEJMoa1308345

    Article  CAS  PubMed  Google Scholar 

  35. Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA et al (2013) Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol 31(32):4085–4091

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG et al (2008) Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol 9(1):29–38

    Article  PubMed  Google Scholar 

  37. Tang X, Yin X, Zhang T, Peng H (2011) The effect of hyperbaric oxygen on clinical outcome of patients after resection of meningiomas with conspicuous peritumoral brain edema. Undersea Hyperb Med 38(2):109–115

    PubMed  Google Scholar 

  38. Chamberlain MC, Glantz MJ (2008) Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas. Cancer 113(8):2146–2151. http://www.ncbi.nlm.nih.gov/pubmed/18756531

    Article  CAS  PubMed  Google Scholar 

  39. Maier-Hauff K, Ulrich F, Nestler D, Niehoff H, Wust P, Thiesen B et al (2010) Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J Neurooncol. http://www.ncbi.nlm.nih.gov/pubmed/20845061

  40. Simó M, Argyriou AA, Macià M, Plans G, Majós C, Vidal N et al (2014) Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy. Cancer Chemother Pharmacol 73(5):919–923

    Article  CAS  PubMed  Google Scholar 

  41. Iwamoto FM, Lamborn KR, Robins HI, Mehta MP, Chang SM, Butowski NA et al (2010) Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol 12(8):855–861

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Desjardins A, Reardon DA, Coan A, Marcello J, Herndon JE, Bailey L et al (2012) Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer 118(5):1302–1312

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Neuromodulation, Center of Clinical Research Learning, Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, MA, USA

    Aline Patrícia Briet, Beatriz Teixeira Costa, Isadora Santos Ferreira, Rivadávio Fernandes Batista de Amorin & Felipe Fregni

Authors
  1. Aline Patrícia Briet
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Beatriz Teixeira Costa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Isadora Santos Ferreira
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rivadávio Fernandes Batista de Amorin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Felipe Fregni
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Felipe Fregni .

Editor information

Editors and Affiliations

  1. Laboratory of Neuromodulation, Center of Clinical Research Learning, Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, Massachusetts, USA

    Felipe Fregni

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Briet, A.P., Costa, B.T., Ferreira, I.S., de Amorin, R.F.B., Fregni, F. (2018). Tumors of the Central Nervous System. In: Fregni, F. (eds) Clinical Trials in Neurology. Neuromethods, vol 138. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7880-9_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-7880-9_10

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-7879-3

  • Online ISBN: 978-1-4939-7880-9

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation